We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Burzynski Research Institute (BZYR)

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: paul j. gourley who wrote (10)12/14/1997 11:03:00 PM
From: mike head  Read Replies (1) of 15
OK, Paul, here it is (I hope)

ÿ Tell Me More - From Infoseek

Burzynski Research Institute Advances Clinical Trials for New Cancer Treatment and Completes New SEC Filing

December 10, 1997 11:26 AM EST

HOUSTON--(BUSINESS WIRE)--Dec. 10, 1997--Burzynski Research Institute Inc. (OTC Bulletin Board: BZYR) has filed a Form 10SB with the Securities and Exchange Commission which will make it a reporting company and allow the Company's stock to be marketed and supported by NASD broker/dealers.

Additionally, the Company announced a new clinical trial earlier this year for its experimental drugs, ANTINEOPLASTONS, for the treatment of liver cancer. Currently, Burzynski Research Institute is sponsoring a total of 72 Phase II Clinical Trials of ANTINEOPLASTONS in the treatment of a variety of cancer types and advanced stages. Early clinical results indicate particular promise with malignant brain tumors and lymphomas.

An interim analysis of three clinical studies indicates that from 33% to 50% of evaluable brain tumor patients accomplished either complete tumor elimination or reduction of tumor size by more than 50%.

ANTINEOPLASTONS are peptides, amino acid derivatives and certain organic acids that occur naturally in healthy individuals and, according to CEO and founder, Stanislaw R. Burzynski, M.D., Ph.D., may constitute the body's first and most effective line of defense against cancer.

The Company plans to submit the results of its current clinical trials to the FDA in January, 1998. If FDA finds the results of the trials sufficiently promising, Burzynski Research Institute Inc. will initiate a procedure to generate data which will support a New Drug Application (NDA).

Burzynski Research Institute stock is publicly traded on the OTC. Earlier this year, BRI retained the services of Brewer-Gruenert Capital Advisors, L.L.C., in Houston, to guide the Company in preparing for expected growth based upon its expectations of the positive results of the latest round of clinical trials.

c Business Wire. All rights reserved.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext